Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...

Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., announced new findings that show MHC-II protein expression is a more reliable predictor of response to pembrolizumab (Keytruda®) than the ...

How does the gut cause Multiple Sclerosis? New research identifies the MHC II protein in intestinal epithelial cells as the trigger for MS-related neuroinflammation. Discover how gut-primed T cells ...

Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.

Controlling infectious diseases—especially zoonoses—is critical for both the economy and public health. Developing safe, effective vaccines remains the most reliable strategy for disease control, but ...

Researchers from Peking University discovered a tumor-specific biomarker that can predict which gastric cancer patients will ...

Recent analyses show that Omicron variants of SARS-CoV-2 more strongly suppress major histocompatibility complex class I expression than previous versions of the virus. Throughout the pandemic, the ...

A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients ...